Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 absolute oral bioavailability study in healthy volunteers
NCT05707403Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nerandomilast, sponsored by Boehringer Ingelheim. Primary endpoint: Dose Normalized Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 216 hours. Started Feb 2023; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT05707403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707403.